Showing results (1-10 of 27) with videos related to

Sort By:
Pageof 3
Clinical Advances in Hematology & Oncology : H&O|May 13, 2024
Increasing inclusion and equity for Black women in breast cancer clinical trialsAmmanuel Taye, Ahmed Elkhanany, Erica Stringer-Reasor
The Surgical Clinics of North America|July 15, 2018
Future Developments in Neoadjuvant Therapy for Triple-Negative Breast CancerLakisha Moore-Smith, Andres Forero-Torres, Erica Stringer-Reasor
Cancer Medicine|December 21, 2025
Socioeconomic- and Insurance-Based Inequities in Oncotype DX Testing and Score-Guided TreatmentCourtney P Williams, Jessica Shuey, Joud El Dick, et al.
JNCI Cancer Spectrum|May 4, 2026
Financial reimbursement for clinical trial participation costs: a pilot feasibility studyCourtney P Williams, Nicole L Henderson, Nusrat Jahan, et al.
Oncogene|November 3, 2021
CRISPR interference and activation of the microRNA-3662-HBP1 axis control progression of triple-negative breast cancerBaozhu Yi, Shuaibin Wang, Xinran Wang, et al.
Annals of Surgical Oncology|December 9, 2024
Therapeutic Clinical Trial Eligibility and Enrollment among Women with Breast Cancer: Implications for Understanding Trial DisparitiesNicole Reh, Nicole E Caston, Courtney P Williams, et al.
Molecular Cancer|February 8, 2022
Dual CRISPR interference and activation for targeted reactivation of X-linked endogenous FOXP3 in human breast cancer cellsXuelian Cui, Chao Zhang, Zhifang Xu, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|June 5, 2025
Quantitative [<sup>89</sup>Zr]Zr-Trastuzumab PET and Diffusion- Weighted MRI for Characterization of Metastatic HER2-Positive Breast Cancer with PET/MRIAmeer Mansur, Jonathan E McConathy, Erica Stringer-Reasor, et al.
Breast Cancer Research : BCR|June 23, 2017
MicroRNA-200c and microRNA- 141 are regulated by a FOXP3-KAT2B axis and associated with tumor metastasis in breast cancerGuangxin Zhang, Wei Zhang, Bingjin Li, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 4, 2024
Cardiac Dysfunction Among Breast Cancer Survivors: Role of Cardiotoxic Therapy and Cardiovascular Risk FactorsGeoffrey Bostany, Yanjun Chen, Liton Francisco, et al.
Pageof 3